SG11202012715UA - Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a - Google Patents
Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2aInfo
- Publication number
- SG11202012715UA SG11202012715UA SG11202012715UA SG11202012715UA SG11202012715UA SG 11202012715U A SG11202012715U A SG 11202012715UA SG 11202012715U A SG11202012715U A SG 11202012715UA SG 11202012715U A SG11202012715U A SG 11202012715UA SG 11202012715U A SG11202012715U A SG 11202012715UA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- associated virus
- muscular dystrophy
- recombinant adeno
- girdle muscular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862691934P | 2018-06-29 | 2018-06-29 | |
| US201962865081P | 2019-06-21 | 2019-06-21 | |
| PCT/US2019/039893 WO2020006458A1 (en) | 2018-06-29 | 2019-06-28 | Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012715UA true SG11202012715UA (en) | 2021-01-28 |
Family
ID=67544319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012715UA SG11202012715UA (en) | 2018-06-29 | 2019-06-28 | Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210277362A1 (en) |
| EP (1) | EP3814514A1 (en) |
| JP (1) | JP2021528983A (en) |
| KR (1) | KR20210028162A (en) |
| CN (1) | CN112543810A (en) |
| AU (1) | AU2019295779A1 (en) |
| BR (1) | BR112020026853A2 (en) |
| CA (1) | CA3105216A1 (en) |
| CL (1) | CL2020003384A1 (en) |
| CO (1) | CO2021000914A2 (en) |
| IL (1) | IL279789A (en) |
| MX (1) | MX2020014119A (en) |
| SG (1) | SG11202012715UA (en) |
| TW (1) | TW202020161A (en) |
| WO (1) | WO2020006458A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021257595A1 (en) | 2020-06-15 | 2021-12-23 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery for muscular dystrophies |
| EP4108263A3 (en) | 2021-06-02 | 2023-03-22 | Research Institute at Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a |
| USD1008419S1 (en) * | 2021-06-14 | 2023-12-19 | Jong Won Kim | Vent valve of a wastewater drainage pipe |
| EP4198048A1 (en) | 2021-12-16 | 2023-06-21 | Genethon | Calpain-3 gene transfer increase using modified itr sequences |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| PT728214E (en) | 1993-11-09 | 2004-11-30 | Ohio Med College | CELL LINES ARE ABLE TO EXPRESS THE ADDITIONAL-ASSOCIATED VIRUS REPLICATION GENE |
| AU688428B2 (en) | 1993-11-09 | 1998-03-12 | Johns Hopkins University, The | Generation of high titers of recombinant AAV vectors |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| FR2737730B1 (en) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | PROCESS FOR PURIFYING VIRUSES BY CHROMATOGRAPHY |
| CA2625279A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
| EP1983057A3 (en) | 1995-09-08 | 2009-01-07 | Genzyme Corporation | Improved AAV vectors for gene therapy |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| KR20000068501A (en) | 1996-09-06 | 2000-11-25 | 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Method for recombinant adeno-associated virus-directed gene therapy |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| EP1009808B1 (en) | 1997-09-05 | 2012-12-05 | Genzyme Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| WO2001083692A2 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
| AU2002248297A1 (en) | 2001-01-05 | 2002-07-16 | Children's Hospital, Inc. | Aav2 vectors and methods |
| US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| DE102012007232B4 (en) | 2012-04-07 | 2014-03-13 | Susanne Weller | Method for producing rotating electrical machines |
| FR3004463A1 (en) * | 2013-04-11 | 2014-10-17 | Genethon | EXPRESSION SYSTEM FOR SELECTIVE GENE THERAPY |
| JP2015092462A (en) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | Positive electrode and lithium ion secondary battery using the same |
| WO2015141521A1 (en) | 2014-03-21 | 2015-09-24 | 株式会社日立国際電気 | Substrate processing apparatus, semiconductor device manufacturing method, and recording medium |
| JP6197169B2 (en) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | Manufacturing method of semiconductor device |
| BR112018009954A2 (en) * | 2015-11-16 | 2018-11-13 | Res Inst Nationwide Childrens Hospital | materials and methods for the treatment of titin-based myopathies and other titinopathies |
| CA3021057A1 (en) * | 2016-04-15 | 2017-10-19 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy |
-
2019
- 2019-06-28 CN CN201980044250.6A patent/CN112543810A/en active Pending
- 2019-06-28 SG SG11202012715UA patent/SG11202012715UA/en unknown
- 2019-06-28 AU AU2019295779A patent/AU2019295779A1/en active Pending
- 2019-06-28 US US17/255,488 patent/US20210277362A1/en active Pending
- 2019-06-28 CA CA3105216A patent/CA3105216A1/en active Pending
- 2019-06-28 KR KR1020207037223A patent/KR20210028162A/en unknown
- 2019-06-28 TW TW108123006A patent/TW202020161A/en unknown
- 2019-06-28 WO PCT/US2019/039893 patent/WO2020006458A1/en active Application Filing
- 2019-06-28 MX MX2020014119A patent/MX2020014119A/en unknown
- 2019-06-28 EP EP19749867.8A patent/EP3814514A1/en active Pending
- 2019-06-28 BR BR112020026853-4A patent/BR112020026853A2/en unknown
- 2019-06-28 JP JP2020572953A patent/JP2021528983A/en active Pending
-
2020
- 2020-12-24 CL CL2020003384A patent/CL2020003384A1/en unknown
- 2020-12-27 IL IL279789A patent/IL279789A/en unknown
-
2021
- 2021-01-28 CO CONC2021/0000914A patent/CO2021000914A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020014119A (en) | 2021-06-18 |
| IL279789A (en) | 2021-03-01 |
| EP3814514A1 (en) | 2021-05-05 |
| AU2019295779A1 (en) | 2021-01-28 |
| CL2020003384A1 (en) | 2021-07-23 |
| TW202020161A (en) | 2020-06-01 |
| KR20210028162A (en) | 2021-03-11 |
| CN112543810A (en) | 2021-03-23 |
| CA3105216A1 (en) | 2020-01-02 |
| CO2021000914A2 (en) | 2021-02-08 |
| US20210277362A1 (en) | 2021-09-09 |
| JP2021528983A (en) | 2021-10-28 |
| BR112020026853A2 (en) | 2021-04-20 |
| WO2020006458A1 (en) | 2020-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279789A (en) | Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a | |
| IL272412A (en) | Cytokine conjugates for the treatment of proliferative and infectious diseases | |
| HK1251219A1 (en) | Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection | |
| ZA201806863B (en) | Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy | |
| SG11202005772YA (en) | Mhc class i associated peptides for prevention and treatment of multiple flavi virus | |
| ZA201905851B (en) | Peptides and methods for the treatment of diabetes | |
| FI3773689T3 (en) | Antigenic peptides for prevention and treatment of cancer | |
| IL288533A (en) | Recombinant oncolytic virus, preparation method thereof, use thereof and medicine thereof | |
| PT3612475T (en) | Conveying system, treatment system, and conveying method | |
| IL285849A (en) | Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy | |
| IL272121A (en) | Composition and methods for the treatment of myopia | |
| IL284029A (en) | Peptides for treatment and prevention of diabetes and associated disorders | |
| PL3641795T3 (en) | Methods and materials for treating blood vessels | |
| IL272094A (en) | Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection | |
| IL290734A (en) | Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy | |
| GB201801553D0 (en) | Splinting apparatus and method | |
| ZA202105143B (en) | Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof | |
| EP3261439A4 (en) | Methods and materials for treating human immunodeficiency virus infections | |
| GB201913592D0 (en) | Product for therapy and methods | |
| GB201810635D0 (en) | Peptides and cancer treatment | |
| HUE055697T2 (en) | Method and device for the continuous ozone-based treatment of particulate products, comprising means for conveying and vibrating said products | |
| IL268844A (en) | Peptides and methods of treating dystrophy-related disorders using the same | |
| PT4021505T (en) | Medicament and method for treating infectious diseases | |
| IL292599A (en) | Tmem219 antibodies and therapeutic uses thereof | |
| GB2561823B (en) | Products and methods for hair treatment |